Cargando…

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs

Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens. Polyclonal immunoglobulin preparations such as IVIG and SCIG represe...

Descripción completa

Detalles Bibliográficos
Autores principales: von Gunten, Stephan, Schneider, Christoph, Imamovic, Lejla, Gorochov, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090664/
https://www.ncbi.nlm.nih.gov/pubmed/37063852
http://dx.doi.org/10.3389/fimmu.2023.1166821
_version_ 1785023007415074816
author von Gunten, Stephan
Schneider, Christoph
Imamovic, Lejla
Gorochov, Guy
author_facet von Gunten, Stephan
Schneider, Christoph
Imamovic, Lejla
Gorochov, Guy
author_sort von Gunten, Stephan
collection PubMed
description Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens. Polyclonal immunoglobulin preparations such as IVIG and SCIG represent the IgG repertoire of the donor population and will likely remain the cornerstone of antibody replacement therapy in immunodeficiencies. However, novel evidence suggests that pooled IgA might promote orthobiotic microbial colonization in gut dysbiosis linked to mucosal IgA immunodeficiency. Plasma-derived polyclonal IgG and IgA exhibit immunoregulatory effects by a diversity of different mechanisms, which have inspired the development of novel drugs. Here we highlight recent insights into IgG and IgA repertoires and discuss potential implications for polyclonal immunoglobulin therapy and inspired drugs.
format Online
Article
Text
id pubmed-10090664
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100906642023-04-13 Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs von Gunten, Stephan Schneider, Christoph Imamovic, Lejla Gorochov, Guy Front Immunol Immunology Significant progress has been made in the elucidation of human antibody repertoires. Furthermore, non-canonical functions of antibodies have been identified that reach beyond classical functions linked to protection from pathogens. Polyclonal immunoglobulin preparations such as IVIG and SCIG represent the IgG repertoire of the donor population and will likely remain the cornerstone of antibody replacement therapy in immunodeficiencies. However, novel evidence suggests that pooled IgA might promote orthobiotic microbial colonization in gut dysbiosis linked to mucosal IgA immunodeficiency. Plasma-derived polyclonal IgG and IgA exhibit immunoregulatory effects by a diversity of different mechanisms, which have inspired the development of novel drugs. Here we highlight recent insights into IgG and IgA repertoires and discuss potential implications for polyclonal immunoglobulin therapy and inspired drugs. Frontiers Media S.A. 2023-03-28 /pmc/articles/PMC10090664/ /pubmed/37063852 http://dx.doi.org/10.3389/fimmu.2023.1166821 Text en Copyright © 2023 von Gunten, Schneider, Imamovic and Gorochov https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
von Gunten, Stephan
Schneider, Christoph
Imamovic, Lejla
Gorochov, Guy
Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
title Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
title_full Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
title_fullStr Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
title_full_unstemmed Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
title_short Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
title_sort antibody diversity in ivig: therapeutic opportunities for novel immunotherapeutic drugs
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090664/
https://www.ncbi.nlm.nih.gov/pubmed/37063852
http://dx.doi.org/10.3389/fimmu.2023.1166821
work_keys_str_mv AT vonguntenstephan antibodydiversityinivigtherapeuticopportunitiesfornovelimmunotherapeuticdrugs
AT schneiderchristoph antibodydiversityinivigtherapeuticopportunitiesfornovelimmunotherapeuticdrugs
AT imamoviclejla antibodydiversityinivigtherapeuticopportunitiesfornovelimmunotherapeuticdrugs
AT gorochovguy antibodydiversityinivigtherapeuticopportunitiesfornovelimmunotherapeuticdrugs